188 related articles for article (PubMed ID: 32832623)
1. Inhibition of Polo-like kinase 1 (PLK1) facilitates the elimination of HIV-1 viral reservoirs in CD4
Zhou D; Hayashi T; Jean M; Kong W; Fiches G; Biswas A; Liu S; Yosief HO; Zhang X; Bradner J; Qi J; Zhang W; Santoso N; Zhu J
Sci Adv; 2020 Jul; 6(29):eaba1941. PubMed ID: 32832623
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of polo-like kinase 1 (PLK1) facilitates reactivation of gamma-herpesviruses and their elimination.
Biswas A; Zhou D; Fiches GN; Wu Z; Liu X; Ma Q; Zhao W; Zhu J; Santoso NG
PLoS Pathog; 2021 Jul; 17(7):e1009764. PubMed ID: 34297745
[TBL] [Abstract][Full Text] [Related]
3. Modeling HIV-1 Latency Using Primary CD4
Takata H; Kessing C; Sy A; Lima N; Sciumbata J; Mori L; Jones RB; Chomont N; Michael NL; Valente S; Trautmann L
J Virol; 2019 Jun; 93(11):. PubMed ID: 30918072
[TBL] [Abstract][Full Text] [Related]
4. Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.
Sarracino A; Gharu L; Kula A; Pasternak AO; Avettand-Fenoel V; Rouzioux C; Bardina M; De Wit S; Benkirane M; Berkhout B; Van Lint C; Marcello A
mBio; 2018 Nov; 9(6):. PubMed ID: 30425153
[TBL] [Abstract][Full Text] [Related]
5. Quiescence Promotes Latent HIV Infection and Resistance to Reactivation from Latency with Histone Deacetylase Inhibitors.
Painter MM; Zaikos TD; Collins KL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021396
[TBL] [Abstract][Full Text] [Related]
6. TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4
Duan S; Xu X; Wang J; Huang L; Peng J; Yu T; Zhou Y; Cheng K; Liu S
J Virol; 2021 Aug; 95(17):e0081621. PubMed ID: 34133900
[TBL] [Abstract][Full Text] [Related]
7. Selective BCL-X
Ren Y; Huang SH; Macedo AB; Ward AR; Alberto WDC; Klevorn T; Leyre L; Copertino DC; Mota TM; Chan D; Truong R; Rohwetter T; Zumbo P; Dündar F; Betel D; Kovacs C; Benko E; Bosque A; Jones RB
J Virol; 2021 Jul; 95(15):e0242520. PubMed ID: 33980597
[TBL] [Abstract][Full Text] [Related]
8. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
De la Torre-Tarazona HE; Jiménez R; Bueno P; Camarero S; Román L; Fernández-García JL; Beltrán M; Nothias LF; Cachet X; Paolini J; Litaudon M; Alcami J; Bedoya LM
Biochem Pharmacol; 2020 Jul; 177():113937. PubMed ID: 32224142
[TBL] [Abstract][Full Text] [Related]
9. Polo-like-kinase 1 is a proviral host factor for hepatitis B virus replication.
Diab A; Foca A; Fusil F; Lahlali T; Jalaguier P; Amirache F; N'Guyen L; Isorce N; Cosset FL; Zoulim F; Andrisani O; Durantel D
Hepatology; 2017 Dec; 66(6):1750-1765. PubMed ID: 28445592
[TBL] [Abstract][Full Text] [Related]
10. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
Park JE; Kim TS; Kim BY; Lee KS
Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691
[TBL] [Abstract][Full Text] [Related]
11. Targeting polo-like kinase 1 suppresses essential functions of alloreactive T cells.
Berges C; Chatterjee M; Topp MS; Einsele H
Immunol Res; 2016 Jun; 64(3):687-98. PubMed ID: 26724940
[TBL] [Abstract][Full Text] [Related]
12. Polo-like kinase 1 inhibits the activity of positive transcription elongation factor of RNA Pol II b (P-TEFb).
Jiang L; Huang Y; Deng M; Liu T; Lai W; Ye X
PLoS One; 2013; 8(8):e72289. PubMed ID: 23977272
[TBL] [Abstract][Full Text] [Related]
13. Dysregulation of the polo-like kinase pathway in CD4+ T cells is characteristic of pathogenic simian immunodeficiency virus infection.
Bostik P; Dodd GL; Villinger F; Mayne AE; Ansari AA
J Virol; 2004 Feb; 78(3):1464-72. PubMed ID: 14722302
[TBL] [Abstract][Full Text] [Related]
14. Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells.
Pezuk JA; Brassesco MS; Ramos PMM; Scrideli CA; Tone LG
Anticancer Agents Med Chem; 2017; 17(9):1278-1291. PubMed ID: 28270075
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.
Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A
Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629
[TBL] [Abstract][Full Text] [Related]
16. The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency.
de Armas LR; Gavegnano C; Pallikkuth S; Rinaldi S; Pan L; Battivelli E; Verdin E; Younis RT; Pahwa R; Williams SL; Schinazi RF; Pahwa S
Front Immunol; 2021; 12():720697. PubMed ID: 34531866
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1.
Srinivasrao G; Park JE; Kim S; Ahn M; Cheong C; Nam KY; Gunasekaran P; Hwang E; Kim NH; Shin SY; Lee KS; Ryu E; Bang JK
PLoS One; 2014; 9(9):e107432. PubMed ID: 25211362
[TBL] [Abstract][Full Text] [Related]
18. From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.
Shan L; Siliciano RF
Bioessays; 2013 Jun; 35(6):544-52. PubMed ID: 23613347
[TBL] [Abstract][Full Text] [Related]
19. Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents.
Passaes CPB; Bruel T; Decalf J; David A; Angin M; Monceaux V; Muller-Trutwin M; Noel N; Bourdic K; Lambotte O; Albert ML; Duffy D; Schwartz O; Sáez-Cirión A
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077644
[TBL] [Abstract][Full Text] [Related]
20. Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
Acchioni C; Remoli AL; Marsili G; Acchioni M; Nardolillo I; Orsatti R; Farcomeni S; Palermo E; Perrotti E; Barreca ML; Sabatini S; Sandini S; Parolin C; Lin R; Borsetti A; Hiscott J; Sgarbanti M
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
